Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that it will present three posters, including two late breaker abstracts, at the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) during The International Liver Congress 2015. Poster presentations will include Phase 1 results on ACH-3422, a NS5B nucleotide polymerase inhibitor, and detailed results from the Phase 2 proxy study evaluating ACH-3102, a second-generation NS5A inhibitor, and sofosbuvir following 6- and 8-week treatment durations for treatment-naïve genotype 1 HCV. The congress is being held April 22 – 26 in Vienna, Austria. The abstracts can be accessed on the EASL website at https://ilc-congress.eu/ and posters will be available following their presentation under the resources section of the Achillion website at http://www.achillion.com.

Thursday, April 23, 2015

  • LP06: Sustained virologic response after ACH-3102 and sofosbuvir treatment for 8 or 6 weeks: A phase 2 “proxy” study ACH102-017. ePoster Presentation, April 23-25, 7:30 am – 8:00 pm CET, Hall B ePoster Area. Lead Author: Edward Gane.
  • LP27: Gane, E., et al. ACH-3422, a novel nucleotide prodrug inhibitor of HCV NS5B polymerase. ePoster Presentation, April 23-25, 7:30 am – 8:00 pm CET, Hall B ePoster Area. Lead Author: Edward Gane.
  • P0805: Achievement of SVR12 despite the presence of HCV variants resistant to first generation NS5A inhibitors in genotype-1 hepatitis C patients after 8-week therapy of ACH-3102 in combination with sofosbuvir. ePoster Presentation, April 23-25, 7:30 am – 8:00 pm CET, Hall B ePoster Area. Lead Author: Wengang Yang. (Original Source)

Shares of Achillion closed yesterday at $9.95 . ACHN has a 1-year high of $16.87 and a 1-year low of $2.45. The stock’s 50-day moving average is $11.23 and it’s 200-day moving average is $12.20.

On the ratings front, Achillion has been the subject of a number of recent research reports. In a report issued on March 10, Maxim Group analyst Jason Kolbert reiterated a Buy rating on ACHN, with a price target of $19, which represents a potential upside of 91.0% from where the stock is currently trading. Separately, on March 3, Barclays’ Geoff Meacham initiated coverage with a Sell rating on the stock and has a price target of $8.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Geoff Meacham have a total average return of 10.6% and 31.6% respectively. Kolbert has a success rate of 45.1% and is ranked #290 out of 3569 analysts, while Meacham has a success rate of 84.6% and is ranked #92.

The street is mostly Bullish on ACHN stock. Out of 5 analysts who cover the stock, 4 suggest a Buy rating and one recommend to Sell the stock. The 12-month average price target assigned to the stock is $19.00, which represents a potential upside of 91.0% from where the stock is currently trading.

Achillion Pharmaceuticals Inc is a biopharmaceutical company which focuses on the discovery, development and commercialization of treatments for infectious diseases likehepatitis C virus, or HCV, infection that are once-daily and ribavirin-free.